CARsgen Therapeutics grabs $30 mln Series B
China-based CARsgen Therapeutics, an immunotherapy company that focuses on treating various cancers, has closed $30 million in Series B funding. KTB Ventures and Jolly Innovation Ventures led the round with participation from Kaitai Capital and JIC GenesisFountain Healthcare Ventures. In addition to the funding, Chi Hoon Hyun of KTB Ventures has been added to CARsgen's board of directors.
25 January 2016•3 mins read
